Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Incannex Healthcare (IXHL) Research & Development (2023 - 2025)

Historic Research & Development for Incannex Healthcare (IXHL) over the last 3 years, with Q3 2025 value amounting to $1.1 million.

  • Incannex Healthcare's Research & Development fell 6132.6% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year decrease of 3188.31%. This contributed to the annual value of $10.7 million for FY2025, which is 1655.41% down from last year.
  • Per Incannex Healthcare's latest filing, its Research & Development stood at $1.1 million for Q3 2025, which was down 6132.6% from $3.7 million recorded in Q2 2025.
  • Incannex Healthcare's 5-year Research & Development high stood at $4.4 million for Q2 2024, and its period low was $1.1 million during Q3 2025.
  • Its 3-year average for Research & Development is $2.7 million, with a median of $2.7 million in 2025.
  • Its Research & Development has fluctuated over the past 5 years, first soared by 1104.29% in 2024, then crashed by 6132.6% in 2025.
  • Incannex Healthcare's Research & Development (Quarter) stood at $2.6 million in 2023, then crashed by 46.4% to $1.4 million in 2024, then decreased by 20.79% to $1.1 million in 2025.
  • Its Research & Development stands at $1.1 million for Q3 2025, versus $3.7 million for Q2 2025 and $2.7 million for Q1 2025.